You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NHLBI

    Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid, Accurate Point-of-Care Test for Gonorrhea and Determination of Antimicrobial Susceptibility

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    Antimicrobial resistant gonorrheacaused by Neisseria gonorrhoeaeNGhas become an urgent threat for global public healthThe goal of this project is to develop a one hour point of care diagnosticPOCtest capable of identifying NGand determining the infecting strain s susceptibility to antibioticsAI Biosciences plans to achieve this goal by expanding the capability of its POC system being developed for ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NIAID

    This goal of this program is to address the limited availability of reagentsantibodiesproteinsligandsfor the identification and discrimination of immune cells and the characterization of immune responses in nonmammalian models and mammalian models for which immunologic reagents are limitede gguinea pigferretcotton ratFor examplethe progression of disease that follows infection of guinea pigs with ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. NCATS SBIR 2019 PHASE I PROPOSALS TOPIC 018 ENTITLED NON-PDMS BIOCOMPATIBLE ALTERNATIVES FOR ORGANS-ON-CHIPS

    SBC: LYNNTECH INC.            Topic: NIDA

    Microfluidic organ on a chipOOCsystems offer a distinct advantage over existing in vitro systems through incorporation of micro architecture to a cultured cell line sthat structurely and mechanically mimic more closely in vivo physiological conditions in an in vitro constructThese OOC devices are typically constructed from polydimethylsiloxanePDMShoweverPDMS has several drawbacks that can impact t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIDA

    Project Summary Abstract Under this Fast Track proposalwe will develop Fenrockan abuse deterrent transdermal fentanyl patch based on our proprietary co crystal of naltrexoneNTXand its carefully selected conformermethyl furfuralMFFThis NTXMFFco crystalNTX Cohas the desired properties to stay in a crystalline solid form in the patch when applied to skin as intended but to dissociate to deliver NTX w ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Noninvasive Home Assessment of Cardiac Filling Pressure to Identify Heart Failure Patients at High Risk for Readmission

    SBC: Vixiar Medical, Inc            Topic: NHLBI

    Congestive heart failure (CHF) is the most common reason for hospitalization in the U.S., with over 1 million admissions per year. Patients admitted with CHF usually need IV diuretics to promote fluid removal. The readmission rate is high – over 20% by 30 days, and 30% by 90 days post-discharge. This also presents an enormous economic burden - hospitalizations account for a large percentage of t ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Neonatal Abstinence Syndrome Therapy

    SBC: Mu Therapeutics Inc.            Topic: NIDA

    Neonatal Abstinence Syndrome (NAS) has skyrocketed in recent years as a result of the opioid epidemic plaguing this country. Since 2000, the number of babies affected by NAS has increased nearly 5-fold. Every 25 minutes a baby is born suffering from opioid withdrawal, often prematurely with developmental problems and potential long-term adverse effects including cognitive impairment. Approximately ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Solid-phase replication of long template libraries for NGS applications

    SBC: REDVAULT BIOSCIENCES LP            Topic: 100

    The rapid development of next generation sequencingNGStechnologies has allowed researchers to make unprecedented progress in the analysis of genomesthe results of which have profound implications for human healthThe ability to fully characterize genomes remains unrealizedhoweverdue in large part to our inability to reconcile sequence information over long distancesCurrent long readlong templateand ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR Phase II: Protein A Membrane Columns for Rapid Protein Purification

    SBC: Purilogics, LLC            Topic: 400

    Project Summary This SBIR Urgent Competitive Revision will develop the first affinity membrane to purify therapeutic mRNA with high selectivity and throughput. mRNA-based pharmaceuticals have potential to address a wide variety of pathologies. mRNA-based vaccines can increase safety and dramatically shorten development timelines in pandemic scenarios. A number of mRNA-based COVID-19 vaccines are u ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government